Procyrion is proud to be recognized as a Fierce15 Medtech company this year! Check out the interview with our CEO Eric Fain to learn more about our innovative Aortix™ technology and the potential it has to change the way patients with acute decompensated heart failure and cardiorenal syndrome are treated.
Procyrion awarded the Most Innovative Heart Pump Technology award in the 2018 Global Healthcare and Pharmaceutical Awards for their device, Aortix™, a catheter-deployed circulatory support device designed initially to address cardiorenal syndrome in heart failure patients.
Katherine Cox, Procyrion's Senior Director of Quality Assurance, awarded Quality Magazine's Professional of the Year Award at the 2017 Quality Show
Founded in 2005, Procyrion, Inc. has identified an opportunity in the sweet spot—the time between when the drugs start to fail and a last-resort surgical intervention—to treat millions of NYHA Class III-IVa heart failure patients using a novel and minimally invasive catheter-based heart pump, Aortix.
Houston heart pump developer Procyrion Inc. today announced they have won the Medical Device and Diagnostic Imaging (MD+DI) Magazine’s 2016 MedTech Startup Showdown Challenge with their ground breaking technology, Aortix™, a catheter-based circulatory support device.
Procyrion Inc. today announced they have won the Johnson & Johnson Quick Fire Challenge with their ground breaking technology, Aortix™, a catheter-based circulatory support device. Procyrion has been awarded a year residency in the new JLABS facility located within the Texas Medical Center’s Innovation Institute.
The 13th annual "Create the Future" Design Contest for engineers, students and entrepreneurs worldwide attracted a record number of entries - nearly 1,160 innovative product ideas from engineers and students in more than 60 countries.
Procyrion, Inc. of Houston, TX is developing the first catheter-deployed heart pump intended for long-term treatment of chronic heart failure. Thinner than a #2 pencil and only 6cm long, AortixTM has the potential to become a low-risk circulatory assist device for a broad range of patients.
Procyrion Inc. today earned the 2015 Universal Biotech Innovation Prize for Aortix™, a catheter-based circulatory support device. With the top two most innovative projects, Procyrion and Pixium Vision, will share a grant award and a year of consulting services offered by organizer Universal Biotech, valued at €60,000.
Houston, Texas-based startup Procyrion, Inc. has been selected as one of the semi finalists for the 7th Universal Biotech Innovation Prize 2015, for the development of the Aortix heart pump system for patients with chronic heart failure.
Procyrion (Houston, TX) is addressing heart failure with Aortix, a catheter-deployed micro-pump. Thinner than a #2 pencil, Aortix augments heart function by reducing afterload, allowing the heart to work at a sustainable level while perfusing vital organs.
A number of Houston companies made their presence known at Austin's SXSW Interactive festival this year. Procyrion's Jace Heuring giving his pitch at the 2015 Hatch Pitch competition.
Procyrion Inc., a medical device firm developing the first catheter-deployed circulatory assist device intended for long-term use in the treatment of chronic heart failure, has been awarded a $50,000 grant from the National Capital Consortium for Pediatric Device Innovation.
A life-long do-it-yourselfer, Will Clifton is now involved with the development of the Procyrion Aortix—a small LVAD meant to be implanted inside an artery in a minimally invasive procedure. Clifton has managed Procyrion's Preclinical R&D program including sourcing sites, drafting protocols, and executing studies.
Procyrion recognized by the Rice Alliance as a “Top Life Science Company” for its Aortix™ medical device.
Ben Hertzog, CEO of Houston-based Procyrion, said he's excited about the company's recently awarded $750,000 Emerging Technology Fund grant.
The Goradia Innovation Prize, with Opportunity Houston, distributes almost $150,000 in cash prizes to finalists and honorable mentions of early stage companies that have commercialized or will soon commercialize innovative technology within the Gulf Coast region at the 2012 Innovation Conference and Showcase.
